Differences in TP53 status fundamentally altered early cellular responses to decitabine in a model of #myelodysplasticSyndrome. Published in @jcb.org and @rarediseaseadvisor.bsky.social.
https://bit.ly/4jDZYLL
#MDS
https://bit.ly/4jDZYLL
#MDS
TP53 Status Shapes Early Decitabine Response in MDS Cells
Multiomics integration identified 31 candidate genes that may underlie early decitabine resistance and suggest sensitization strategies.
bit.ly
January 14, 2026 at 5:45 PM
Differences in TP53 status fundamentally altered early cellular responses to decitabine in a model of #myelodysplasticSyndrome. Published in @jcb.org and @rarediseaseadvisor.bsky.social.
https://bit.ly/4jDZYLL
#MDS
https://bit.ly/4jDZYLL
#MDS
Differences in #TP53 status fundamentally altered early cellular responses to decitabine in a model of #MyelodysplasticSyndrome (MDS), revealing molecular features that may contribute to resistance and identify actionable targets.
Read here: https://bit.ly/4s4iQHt
Read here: https://bit.ly/4s4iQHt
TP53 Status Shapes Early Decitabine Response in MDS Cells
TP53 mutation status strongly modifies early transcriptomic, proteomic, and methylation responses to decitabine in MDS models.
bit.ly
December 26, 2025 at 7:53 PM
Differences in #TP53 status fundamentally altered early cellular responses to decitabine in a model of #MyelodysplasticSyndrome (MDS), revealing molecular features that may contribute to resistance and identify actionable targets.
Read here: https://bit.ly/4s4iQHt
Read here: https://bit.ly/4s4iQHt
A TMEM91::TAL1 gene fusion was found for the first time in a patient with #MyelodysplasticSyndrome (MDS) progressing to secondary acute myeloid leukemia (#sAML), researchers reported in Hematology.
Read more: https://bit.ly/3L6cR4h
#RareDisease #GeneFusion #MDS #Hematology
Read more: https://bit.ly/3L6cR4h
#RareDisease #GeneFusion #MDS #Hematology
Novel Gene Fusion Detected in Patient With MDS
Previously detected in glioblastoma, the TMEM91::TAL1 gene fusion has not been documented in myelodysplastic syndromes (MDS) until now.
www.rarediseaseadvisor.com
December 19, 2025 at 6:53 PM
A TMEM91::TAL1 gene fusion was found for the first time in a patient with #MyelodysplasticSyndrome (MDS) progressing to secondary acute myeloid leukemia (#sAML), researchers reported in Hematology.
Read more: https://bit.ly/3L6cR4h
#RareDisease #GeneFusion #MDS #Hematology
Read more: https://bit.ly/3L6cR4h
#RareDisease #GeneFusion #MDS #Hematology
What is #MyelodysplasticSyndrome?
Dr. @AshKishtagari is talking about this type of cancer at our #BloodCancersOncTalk 2025!
Join us here --> give.cancergrace.org/event/2025-b...
Dr. @AshKishtagari is talking about this type of cancer at our #BloodCancersOncTalk 2025!
Join us here --> give.cancergrace.org/event/2025-b...
October 25, 2025 at 3:19 PM
What is #MyelodysplasticSyndrome?
Dr. @AshKishtagari is talking about this type of cancer at our #BloodCancersOncTalk 2025!
Join us here --> give.cancergrace.org/event/2025-b...
Dr. @AshKishtagari is talking about this type of cancer at our #BloodCancersOncTalk 2025!
Join us here --> give.cancergrace.org/event/2025-b...
RAS mutations are strong predictors of poor prognosis among adult patients with #myelodysplasticSyndrome. Presented at #ESMO25.
https://bit.ly/47i9xdp
#MDS
https://bit.ly/47i9xdp
#MDS
RAS Mutational Status Predictive of OS, PFS in Adult MDS - Hematology Advisor
Researchers sought to assess whether RAS mutational status was predictive of survival for patients with MDS.
bit.ly
October 23, 2025 at 4:05 PM
RAS mutations are strong predictors of poor prognosis among adult patients with #myelodysplasticSyndrome. Presented at #ESMO25.
https://bit.ly/47i9xdp
#MDS
https://bit.ly/47i9xdp
#MDS
Read the latest Journal of #Infection for the retrospective review of adult patients with acute #Leukemia or #MyelodysplasticSyndrome and culture-positive proven/probable #InvasivePulmonaryAspergillosis 👉 www.journalofinfecti...
September 4, 2025 at 9:00 AM
Read the latest Journal of #Infection for the retrospective review of adult patients with acute #Leukemia or #MyelodysplasticSyndrome and culture-positive proven/probable #InvasivePulmonaryAspergillosis 👉 www.journalofinfecti...
We are honoured to welcome Professor John D. Crispino, from
@stjude.bsky.social as speaker to #NDLR2026. John’s research focuses on mechanisms of #Leukemia development in children with Down syndrome and the malignant progression of #MyelodysplasticSyndrome and #MyeloproliferativeNeoplasms.
@stjude.bsky.social as speaker to #NDLR2026. John’s research focuses on mechanisms of #Leukemia development in children with Down syndrome and the malignant progression of #MyelodysplasticSyndrome and #MyeloproliferativeNeoplasms.
August 19, 2025 at 11:55 PM
We are honoured to welcome Professor John D. Crispino, from
@stjude.bsky.social as speaker to #NDLR2026. John’s research focuses on mechanisms of #Leukemia development in children with Down syndrome and the malignant progression of #MyelodysplasticSyndrome and #MyeloproliferativeNeoplasms.
@stjude.bsky.social as speaker to #NDLR2026. John’s research focuses on mechanisms of #Leukemia development in children with Down syndrome and the malignant progression of #MyelodysplasticSyndrome and #MyeloproliferativeNeoplasms.